Welcome to Drug and Alcohol Treatment
| ||
Drug Treatment Abdominal Pain Article
This is a selection made from among articles on Drug Treatment Abdominal Pain. For a permanent link to this article, or to bookmark it for future reading, click here.
Drug Addiction Rehabilitation: Tailoring The Treatment To The Need
from:by Judy Wellsworth
The intensity of drug addiction rehabilitation required by different addicts will vary according to the severity of their addictions. When addicts admit themselves, or are forcibly admitted, to drug addiction rehabilitation facilities, their physical conditions are evaluated so that an appropriate treatment can be determined. There are different drug addiction rehabilitation programs designed to treat the different levels of addiction.Outpatient Treatmenr and DetoxThere are, at the lowest level of drug addiction rehabilitation, intervention and short duration programs, which do not involve any physical treatment. They include court-ordered attendance at classes on the dangers of driving while intoxicated or visits to rehab units for teens caught using drugs or alcohol who has not yet become addicts. They are designed to steer people off the road to addiction before they have traveled to far down it.Detoxification is the second level of drug addiction rehabilitation; just the opposite of short-term intervention, detoxification treats only the physical nature of addiction. The addict is admitted to a facility, remains until he or she is free of the effects of whatever substances caused the admission, and is released. Inpatient TreatmentThe most comprehensive of all the drug addiction rehabilitation programs is inpatient treatment. Inpatient drug addiction rehabilitation requires addicts to take up residence in the facility where they receive their treatment, and the amount of time they stay will depend on how hard they work on confronting their addictions and learning healthier patterns of behavior. Inpatient drug addiction rehabilitation will first include detoxification, with or without the use of sedatives and pain medications; their inclusion will depend both on whether the addict’s system can handle any more chemicals, and whether those running the program believe going “cold turkey” when withdrawing is the best deterrent to future substance abuse.Once the detoxification is over, the addicts will spend their days learning to take responsibility by having jobs assigned to them; going to individual and group counseling sessions, and getting at the emotional causes underlying their dependencies. The process can last for a month of for a year, depending on the severity of the addiction. Inpatient drug addiction rehabilitation is a last resort.Therapeutic techniques in inpatient facilities may include journaling so that the addicts can learn both self-observation skills and how to recognize the situations in which their cravings for drugs are triggered.Choosing the appropriate drug addiction rehabilitation is a matter of balancing the severity of the addiction with the addict’s desire for recovery.
You can also find more information at Drug Addiction Treatment and Drug Addiction Centers. Drugtreatmentinfo.org is a comprehensive resource to known more about drug addiction.
Drug Treatment Abdominal Pain Specific links
Drug Treatment Abdominal Pain News
First stem cell drug approved for systemic disease treatment
Osiris Therapeutics Inc said on Thursday that Canadian health regulators have approved its treatment for acute graft-versus host disease in children, making it the first stem cell drug to be approved for a systemic disease anywhere in the world
Read more...Canada OKs Osiris drug; first stem cell therapy
BOSTON (Reuters) - Osiris Therapeutics Inc said on Thursday that Canadian health regulators have approved its treatment for acute graft-versus host disease in children, making it the first stem cell drug to be approved for a systemic disease anywhere in the world. Osiris shares rose 14 percent to $6.00 in extended trading after the news was announced. Graft versus host disease (GvHD) is a ...
Read more...Pfizer’s Axitinib Receives Positive Opinion from the Committee for Human Medicinal Products for the Second-line ...
Pfizer announced today that the Committee for Human Medicinal Products of the European Medicines Agency has adopted a positive opinion regarding the marketing authoriz
Read more...FDA warns against multiple sclerosis treatment
The experimental 'liberation therapy,' which involves widening veins in the head and neck to alleviate MS symptoms, has caused death and has no proven benefit, the agency says. WASHINGTON — An experimental treatment for multiple sclerosis has caused death, strokes, nerve damage and abdominal bleeding and has no proven benefits for sufferers of the disease, the Food and Drug Administration warned ...
Read more...Vertex Receives European CHMP Positive Opinion for KALYDECOâ„¢ (ivacaftor), the First Medicine to Treat the Underlying ...
Vertex Pharmaceuticals Incorporated announced today that the European Committee for Medicinal Products for Human Use has issued a positive opinion by consensus recommending the approval of KALYDECOâ„¢ for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.
Read more...Pfizers Axitinib Receives Positive Opinion from the Committee for Human Medicinal Products for the Second-line ...
Pfizer announced today that the Committee for Human Medicinal Products ...
Read more...Cubist sees positive constipation drug candidate data
Cubist Pharmaceuticals Inc. (Nasdaq: CBST) said two of its Phase 2 studies of the drug candidate CB-5945 in patients with chronic non-cancer pain and opioid-induced constipation have met their primary endpoints, and Phase 3 studies are expected to start by the end of this year.
Read more...Ocera gets European approval for IBS drug
San Diego company receives the CE mark of approval for Zysa, its drug to treat diarrhea-predominant irritable bowel syndrome.
Read more...Student endures despite cancer battle
QUINCY, Ill. | During his first two years at Quincy University, Luke Weaver became a familiar figure to many of his fellow students.
Read more...Baxter’s Low Glucose PD Solutions Favorably Impacted Metabolic Measures Including Glycemic Control in Trials of ...
Baxter International Inc. today announced results from two large, international multicenter trials demonstrating that a low glucose peritoneal dialysis regimen favorably impacted metabolic measures important for end-stage renal disease patients with diabetes, including blood glucose control and selected lipids .
Read more...